The global transfection reagent & equipment market size is expected to
reach USD 1.08 billion by 2022, progressing at a CAGR of 7.4%.

The growth of the market can be attributed to ongoing oncology-based
research & development that aimed at understanding disease cause at
genomic & molecular levels coupled with consequent surging demand for
targeted therapies.

Transfection technology is recognized as an integral part of research
programs pertaining to thorough investigation of various chromosomal
anomalies. Hence, rising cancer prevalence of cancer as well as genetic
conditions is anticipated to provide a fillip to the market.
Furthermore, funds and grants by funding and government bodies are
likely to back the growth of the market.

Funding and federal agencies, such as National Science Foundation (NSF),
are offering the biotechnology sector with huge funding to carry out
their biotechnology-based investigational studies. Moreover,
international funding bodies such as NIH and Welcome Trust are projected
to play a crucial role in the growth of the market by providing funds
for genetic research studies. Such significant funds and grants are
poised to boost the adoption of transfection technology over the
forecast period.

Thermo Fisher Scientific Inc., Promega Corporation, QIAGEN, and
F.Hoffmann-La Roche Ltd are some prominent players in the market. These
companies are undertaking several endeavors to enhance their shares in
the market